These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 29866459)

  • 1. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study.
    Bansal N; Zelnick L; Shlipak MG; Anderson A; Christenson R; Deo R; deFilippi C; Feldman H; Lash J; He J; Kusek J; Ky B; Seliger S; Soliman EZ; Go AS;
    Clin Chem; 2019 Nov; 65(11):1448-1457. PubMed ID: 31578216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble ST2 and Galectin-3 as Predictors of Chronic Kidney Disease Progression and Outcomes.
    Kim AJ; Ro H; Kim H; Chang JH; Lee HH; Chung W; Jung JY
    Am J Nephrol; 2021; 52(2):119-130. PubMed ID: 33725696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study.
    Andersson C; Enserro D; Sullivan L; Wang TJ; Januzzi JL; Benjamin EJ; Vita JA; Hamburg NM; Larson MG; Mitchell GF; Vasan RS
    Atherosclerosis; 2016 May; 248():245-51. PubMed ID: 26972631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
    Rabkin SW; Tang JKK
    Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Bansal N; Zelnick LR; Soliman EZ; Anderson A; Christenson R; DeFilippi C; Deo R; Feldman HI; He J; Ky B; Kusek J; Lash J; Seliger S; Shafi T; Wolf M; Go AS; Shlipak MG;
    Am J Kidney Dis; 2021 Jun; 77(6):907-919. PubMed ID: 33309861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD.
    Lidgard B; Zelnickv L; Anderson AH; Feldman H; Go A; He J; Kansal M; Mohanty MJ; Mehta R; Shlipak MG; Soliman E; Weir MR; Bansal N;
    Kidney360; 2022 May; 3(5):859-871. PubMed ID: 36128494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of cardiovascular stress and incident chronic kidney disease.
    Ho JE; Hwang SJ; Wollert KC; Larson MG; Cheng S; Kempf T; Vasan RS; Januzzi JL; Wang TJ; Fox CS
    Clin Chem; 2013 Nov; 59(11):1613-20. PubMed ID: 23873716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Bansal N; Zelnick L; Go A; Anderson A; Christenson R; Deo R; Defilippi C; Lash J; He J; Ky B; Seliger S; Soliman E; Shlipak M; ;
    J Am Heart Assoc; 2019 Nov; 8(21):e012336. PubMed ID: 31645163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.
    Tummalapalli SL; Zelnick LR; Andersen AH; Christenson RH; deFilippi CR; Deo R; Go AS; He J; Ky B; Lash JP; Seliger SL; Soliman EZ; Shlipak MG; Bansal N;
    J Am Heart Assoc; 2020 Jul; 9(13):e014385. PubMed ID: 32578483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Patel DM; Thiessen-Philbrook H; Brown JR; McArthur E; Moledina DG; Mansour SG; Shlipak MG; Koyner JL; Kavsak P; Whitlock RP; Everett AD; Malenka DJ; Garg AX; Coca SG; Parikh CR
    Am Heart J; 2020 Feb; 220():253-263. PubMed ID: 31911262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Correa S; Pena-Esparragoza JK; Scovner KM; Waikar SS; Mc Causland FR
    Am J Kidney Dis; 2020 Jul; 76(1):32-41. PubMed ID: 31864821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients.
    Obokata M; Sunaga H; Ishida H; Ito K; Ogawa T; Ando Y; Kurabayashi M; Negishi K
    Am Heart J; 2016 Sep; 179():29-41. PubMed ID: 27595677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction.
    Plawecki M; Morena M; Kuster N; Chenine L; Leray-Moragues H; Jover B; Fesler P; Lotierzo M; Dupuy AM; Klouche K; Cristol JP
    Mediators Inflamm; 2018; 2018():3952526. PubMed ID: 30402040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.
    Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C
    Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.
    Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T
    J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.